0
Home
Products
MK-4541 – (796885-38-6)
MK-4541 - (796885-38-6)

MK-4541 – (796885-38-6)

MK-4541 is a dual selective androgen receptor modulator (SARM) and 5α-reductase inhibitor (5α-RI) that has garnered attention for its potential in treating prostate cancer. This orally administered drug exhibits a unique pharmacological profile, acting as both an androgen receptor antagonist and a 5α-reductase inhibitor.

Preclinical studies have demonstrated that MK-4541 induces apoptosis in androgen-dependent prostate cancer cells while promoting anabolic effects in muscle and bone tissues. In animal models, MK-4541 has shown significant inhibition of prostate tumor growth, reduction in plasma testosterone levels, and anti-androgenic effects on the seminal vesicles.

Additionally, it has been found to increase lean body mass and improve muscle function in castrated mice, suggesting its potential as an adjuvant therapy to androgen deprivation therapy (ADT). Despite its promising profile, MK-4541 has not yet progressed beyond preclinical studies as of 2020, and its developmental status remains undisclosed by Merck, the company that developed it.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

SKU: 796885-38-6
Category:
Tags: ,

MK-4541 is a dual selective androgen receptor modulator (SARM) and 5α-reductase inhibitor (5α-RI) that has garnered attention for its potential in treating prostate cancer. This orally administered drug exhibits a unique pharmacological profile, acting as both an androgen receptor antagonist and a 5α-reductase inhibitor.

Preclinical studies have demonstrated that MK-4541 induces apoptosis in androgen-dependent prostate cancer cells while promoting anabolic effects in muscle and bone tissues. In animal models, MK-4541 has shown significant inhibition of prostate tumor growth, reduction in plasma testosterone levels, and anti-androgenic effects on the seminal vesicles.

Additionally, it has been found to increase lean body mass and improve muscle function in castrated mice, suggesting its potential as an adjuvant therapy to androgen deprivation therapy (ADT). Despite its promising profile, MK-4541 has not yet progressed beyond preclinical studies as of 2020, and its developmental status remains undisclosed by Merck, the company that developed it.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/MK-4541
https://www.medchemexpress.com/mk-4541.html
https://www.medkoo.com/products/28864
https://go.drugbank.com/drugs/DB17016
https://pubmed.ncbi.nlm.nih.gov/27106747/
Other Names

SCHEMBL14184849, OGBFNZPDLOPGEO-OCWMMRLVSA-N

IUPAC Name

2, 2, 2-trifluoroethyl N-[(1S, 3aS, 3bS, 5aR, 9aR, 9bS, 11aS)-6, 9a, 11a-trimethyl-7-oxo-2, 3, 3a, 3b, 4, 5, 5a, 9b, 10, 11-decahydro-1H-indeno[5, 4-f]quinolin-1-yl]carbamate

CAS

796885-38-6

Molecular Weight

428.5

Molecular Formula

C22H31F3N2O3

SMILES

C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2NC(=O)OCC(F)(F)F)CC[C@@H]4[C@@]3(C=CC(=O)N4C)C

Related products

No products in the cart.